Domainex has been awarded ‘Best CRO’ at the OBN Awards 2020. Dr Tom Mander, CEO, Dr Ray Boffey, Executive Director of Medicines Research, and Dr Cat Stace, Director of Business Development, attended the postponed awards ceremony in London on June 11, 2021.
Domainex has invested in new technology to support its clients’ research needs and secured an out-licencing deal with Invivoscribe of a therapeutic drug candidate to treat patients with multiple myeloma. The company grew its top line by approximately 45% in 2020 and employed over 30 new people to further extend its drug discovery offering, despite the challenges faced as a result of the pandemic.
To support its growth, Domainex launched a new brand and website, and made leadership adjustments. Dr Tom Mander moved from COO to CEO, Dr Eddy Littler returned to the company as Non-Executive Chairman, David Cronk joined as Chief of Staff and Dr Ray Boffey was promoted to Executive Director of Medicines Research.
Presenting Domainex with the award, the judges commented: “The winner in this category were the only finalist that named their customers and provided excellent customer testimonials. They have their own product programme licensed out and have a clear approach to their robust and effective strategy.”
Tom Mander, CEO of Domainex, said: “Customer focus is a core value that we are incredibly proud of at Domainex, and we are delighted that this has been recognised by OBN with this award. I would like to thank our team for their consistent hard work and positive can-do approach while facing the additional challenges created by the pandemic. It is the amazing attitudes of our team that allows Domainex to offer high quality services and remain a leader in the field of drug discovery.”
